Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEKYREE vs NIACOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.
Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.
Treatment of chronic kidney disease in patients with type 2 diabetes,Reduction of albuminuria in chronic kidney disease
Adjunct to diet for reduction of elevated total cholesterol, LDL-C, apo B, and triglyceride levels, and to increase HDL-C in primary hypercholesterolemia and mixed dyslipidemia,Adjunct to diet for reduction of risk of recurrent myocardial infarction in patients with coronary artery disease and hypercholesterolemia,Adjunct to diet for slowing progression of coronary atherosclerosis,Off-label: treatment of pellagra (niacin deficiency)
1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.
Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.
Terminal elimination half-life: 12 hours (range 10-14 h); prolonged in renal impairment (up to 30 h in Cr Cl <30 m L/min)
20–45 minutes for immediate-release niacin; terminal half-life of main metabolites (nicotinuric acid) is approximately 1.5–4 hours; short half-life necessitates multiple daily dosing for lipid effects
Primarily metabolized by CYP3A4; minor contributions from CYP2C8 and CYP2C9.
Hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major, low-affinity high-capacity) and oxidation to N-methylnicotinamide and other metabolites (minor, high-affinity low-capacity). Enzymes involved: nicotinamide N-methyltransferase (NNMT) and aldehyde oxidase.
Renal: 70% (unchanged drug), Biliary/fecal: 30% (metabolites and unchanged drug)
Renal: 60-88% as unchanged drug and metabolites after oral administration; fecal: <2%
95% bound to albumin and alpha-1-acid glycoprotein
<20% bound to albumin; minimal binding to other plasma proteins
0.8-1.2 L/kg (indicates extensive tissue distribution)
0.5–0.7 L/kg; indicates distribution into total body water and some tissue binding
Oral: 60% (range 50-70%; first-pass metabolism reduces bioavailability)
Oral immediate-release: 60–76% (variable due to first-pass metabolism); sustained-release: lower bioavailability (50–60%) due to increased presystemic metabolism
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended for severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
No specific adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation; consider reducing dose or prolonging interval.
Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg/kg intravenously every 4 weeks; Child-Pugh C: not recommended.
Contraindicated in Child-Pugh class B and C; use with caution in mild impairment (Child-Pugh A) with dose reduction of 50% initially.
Safety and efficacy not established in pediatric patients under 18 years.
For hyperlipidemia (off-label): Initial 50–100 mg/kg/day orally divided into 2–3 doses; titrate over 4–6 weeks up to 200–300 mg/kg/day; maximum 6 g/day. Not recommended in children <2 years.
No specific dose adjustment required; consider age-related renal function and comorbidities.
Start at lowest dose (250 mg daily); titrate slowly due to increased risk of flushing, hypotension, and hepatotoxicity; monitor liver function and glucose closely.
None.
None.
Hyperkalemia: Monitor serum potassium regularly; avoid use with strong CYP3A4 inhibitors or potassium supplements.,Acute kidney injury: May occur; assess renal function before initiation.,Adrenal insufficiency: Not studied in patients with adrenal disorders.,Pregnancy: Limited data; avoid use unless benefit outweighs risk.
Hepatotoxicity: elevated liver enzymes, hepatitis; discontinue if persistent elevations occur,Flushing: prostaglandin-mediated, can be reduced by taking aspirin prior; tolerance develops,Hyperuricemia: may precipitate gout,Hyperglycemia: may increase blood glucose; use with caution in diabetes,Peptic ulcer disease: reactivation may occur,Hypotension: can occur, especially with vasoactive drugs
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin),Serum potassium >5.0 m Eq/L at initiation,e GFR <15 m L/min/1.73 m² (not studied),Hypersensitivity to balcinrenone or any excipient
Hypersensitivity to niacin or any component of formulation,Significant or unexplained hepatic dysfunction,Active peptic ulcer disease,Arterial hemorrhage
No known food interactions. Avoid grapefruit juice if patient is on concurrent CYP3A4 substrates (though bevacizumab is not metabolized by CYP enzymes). Maintain adequate hydration to reduce risk of constipation, a common side effect.
Avoid high-fat meals as they may increase risk of flushing. Take with low-fat snack. Alcohol and hot drinks can exacerbate flushing.
First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for fetal growth restriction and oligohydramnios.
FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses have caused fetal abnormalities. First trimester: Avoid use due to theoretical risk of teratogenicity. Second and third trimesters: Use only if clearly needed, as niacin can cause vasodilation and potential hypotension, which may reduce uteroplacental perfusion.
No human data on excretion in breast milk. M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in nursing infant.
Niacin is excreted into human breast milk in minimal amounts; M/P ratio unknown. The American Academy of Pediatrics considers niacin compatible with breastfeeding. However, high maternal doses may lead to adverse effects in the infant due to potential accumulation. Caution is advised; monitor infant for flushing or gastrointestinal disturbances.
No specific dose adjustments recommended based on pharmacokinetic changes. However, monitor therapeutic effect and adjust dose as needed based on clinical response and tolerability.
No specific dose adjustments recommended due to lack of pharmacokinetic studies in pregnant women. However, physiological changes in pregnancy (increased plasma volume, renal clearance) may reduce niacin levels, potentially requiring dose increase. Use the lowest effective dose and avoid extended-release formulations due to higher hepatotoxicity risk. Usual adult doses (500-2000 mg/day) may be used with caution.
BEKYREE (bevacizumab-awwb) is a biosimilar to bevacizumab. Monitor for hypertension, proteinuria, and bleeding. Discontinue 28 days prior to elective surgery. Avoid use in patients with recent hemoptysis or serious hemorrhage. Infusion reactions may occur; premedicate with antihistamines and acetaminophen as per protocol.
Niacor (niacin) can cause profound flushing, which may be mitigated by taking aspirin 30 minutes prior or using extended-release formulations. Monitor liver function and blood glucose, as niacin can elevate transaminases and worsen glycemic control. Patients with gout may experience increased uric acid levels.
Tell your doctor if you have a history of bleeding problems, blood clots, or recent surgery.,Avoid taking aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, coughing up blood, or black/tarry stools immediately.,Women of childbearing age must use effective contraception during therapy and for 6 months after last dose.,Do not breastfeed during treatment and for 6 months after the last dose.,Monitor for signs of hypertension (severe headache, blurred vision) and proteinuria (foamy urine).
Take with food to reduce stomach upset.,Do not crush or chew extended-release tablets.,Flushing is common and may decrease with continued use.,Avoid alcohol and hot beverages near dosing time to reduce flushing.,Report unexplained muscle pain, tenderness, or weakness.,Monitor blood sugar if diabetic.,Do not substitute with dietary supplements without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEKYREE vs NIACOR, answered by our medical review team.
BEKYREE is a Antilipemic Agent that works by BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.. NIACOR is a Antilipemic agent that works by Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEKYREE and NIACOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEKYREE is: 1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.. The standard adult dose of NIACOR is: Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEKYREE and NIACOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEKYREE is classified as Category C. First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for f. NIACOR is classified as Category C. FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses ha. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.